Purple Biotech (PPBT)
(Real Time Quote from BATS)
$2.15 USD
0.00 (0.00%)
Updated Aug 7, 2025 11:40 AM ET
3-Hold of 5 3
C Value D Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PPBT 2.15 0.00(0.00%)
Will PPBT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PPBT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PPBT
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy
What Makes Purple Biotech (PPBT) a New Buy Stock
PPBT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PPBT
Purple Biotech GAAP EPADS of -$0.57
Purple Biotech Reports Second Quarter 2025 Financial Results | PPBT Stock News
Purple Biotech reports Q2 EPS 40c vs $1.80 last year
Purple Biotech (PPBT) Highlights Scientific Progress and Strategic Goals for 2025 | PPBT Stock News
Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical ...